U.S. FDA Extends Review Timeline for INVOKANA® (canagliflozin) Supplemental New Drug Application

The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) today announced that the U.S. Food and Drug Administration (FDA) has extended the review timeline for a supplemental New Drug Application (sNDA) for INVOKANA® (canagliflozin). The sN http://markets.businessinsider.com/news/stocks/u-s-fda-extends-review-timeline-for-invokana-canagliflozin-supplemental-new-drug-application-1027367096